Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia
S Kiehlmeier, MR Rafiee, A Bakr, J Mika, S Kruse… - Leukemia, 2021 - nature.com
Deregulation of the EVI1 proto-oncogene by the GATA2 distal hematopoietic enhancer
(G2DHE) is a key event in high-risk acute myeloid leukemia carrying 3q21q26 aberrations …
(G2DHE) is a key event in high-risk acute myeloid leukemia carrying 3q21q26 aberrations …
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk …
Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have poor outcomes
and hematopoietic cell transplantation (HCT) is the only curative treatment. New targeted …
and hematopoietic cell transplantation (HCT) is the only curative treatment. New targeted …
A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre-B Acute Lymphoblastic Leukemia
Background: Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of
cancer therapy. After alkylating agents, this typically occurs years after completion of …
cancer therapy. After alkylating agents, this typically occurs years after completion of …